Welcome to
WE AIM TO PROVIDE RARE DISEASE PATIENTS WITH THERAPIES THAT SIGNIFICANTLY IMPROVE THEIR CONDITION AND QUALITY OF LIFE, ALLOWING THEM TO LIVE THEIR BEST POSSIBLE LIVES AND ACHIEVE THEIR FULL POTENTIAL
Relief Therapeutics is a Swiss, commercial - stage biopharmaceutical company, developing and commercializing novel, patent-protected products in selected specialty, rare and ultra-rare diseases.
Latest News
-
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
13 December 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
4 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
21 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
8 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
4 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
23 September 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
18 September 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
2 September 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
30 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Secures up to $11 Million from Royalty Sales
5 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
26 April 2024 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
1 September 2023 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
19 July 2023 | Ad Hoc Announcement pursuant to Art. 53 LRRelief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
15 May 2023 | Ad Hoc Announcement pursuant to Art. 53 LR